source
- RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPACRare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugArgenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.